GENERAL23 Sept 2026
Supreme Court questions 10x gap in retailer price vs MRP of cancer drugs
The Supreme Court called it "absolutely shocking" that an essential cancer drug's printed maximum retail price (MRP) was ₹27,000 while retailers paid just ₹2,700. The court also flagged how high medicine prices hurt patients, especially when treatment is funded through government health schemes. For business owners, this points to closer scrutiny of medicine pricing. Keep your purchase and billing records tidy.
Key Statutory Highlights
- The Supreme Court said it was "absolutely shocking" that the printed MRP of an essential cancer drug was ₹27,000 when the price to the retailer was ₹2,700.
- The court highlighted the impact of high medicine prices on patients.
- The court noted this matters particularly when treatment is funded through government health schemes.
Actionable Advice for Taxpayers / Founders:If your business buys or bills medicines, keep your purchase invoices and billing records accurate and easy to produce, since pricing in this sector is drawing judicial attention. For advice on your own facts, consult a qualified professional.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: